Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies.
No Thumbnail Available
Authors
Li, Jiaqi
Lim, Justin Yi Shen
Eu, Jie Qing
Chan, Andrew Kieran Ming Hui
Goh, Boon Cher
Wang, Lingzhi
Wong, Andrea Li-Ann
Issue Date
2024-04-01
Type
Journal Article
Review
Review
Language
en
Keywords
ROS-inducing drugs , cancer treatment , oxidative stress , reactive oxygen species
Alternative Title
Abstract
Reactive oxygen species (ROS) are generated during mitochondrial oxidative metabolism, and are tightly controlled through homeostatic mechanisms to maintain intracellular redox, regulating growth and proliferation in healthy cells. However, ROS production is perturbed in cancers where abnormal accumulation of ROS leads to oxidative stress and genomic instability, triggering oncogenic signaling pathways on one hand, while increasing oxidative damage and triggering ROS-dependent death signaling on the other. Our review illuminates how critical interactions between ROS and oncogenic signaling, the tumor microenvironment, and DNA damage response (DDR) pathways have led to interest in ROS modulation as a means of enhancing existing anticancer strategies and developing new therapeutic opportunities. ROS equilibrium exists a delicate balance of pro-oxidant and antioxidant species within cells. "Antioxidant" approaches have been explored mainly in the form of chemoprevention, but there is insufficient evidence to advocate its routine application. More progress has been made the "pro-oxidant" approach of targeting cancer vulnerabilities and inducing oxidative stress. Various therapeutic modalities have employed this approach, including direct ROS-inducing agents, chemotherapy, targeted therapies, DDR therapies, radiotherapy, and immunotherapy. Finally, emerging delivery systems such as "nanosensitizers" as radiotherapy enhancers are currently in development. While approaches designed to induce ROS have shown considerable promise in selectively targeting cancer cells and dealing with resistance to conventional therapies, most are still in early phases of development and challenges remain. Further research should endeavor to refine treatment strategies, optimize drug combinations, and identify predictive biomarkers of ROS-based cancer therapies.
Description
Citation
Li, J.; Lim, JYS.; Eu, JQ.; Chan, AKMH.; Goh, BC.; Wang, L. and Wong, AL. (2024) 'Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies', Antioxidants & Redox Signaling 41(4-6) pp. 322-341. Available at: https://doi.org/10.1089/ars.2023.0445
Publisher
Mary Ann Liebert, Inc.
License
Journal
Antioxidants & redox signaling
Volume
41
Issue
4-6
PubMed ID
ISSN
1557-7716